Mehlisch Donald R, Ardia Alfredo, Pallotta Teresa
Scirex Corporation, Austin, Texas, and.
Zambon Group S.p.A., Milan, Italy.
Curr Ther Res Clin Exp. 2003 Jun;64(6):327-37. doi: 10.1016/S0011-393X(03)00104-8.
Dysmenorrhea produces painful abdominal cramps that can disrupt the personal lives and productivity of women.
The aim of this study was to compare the analgesic efficacy, including onset and duration of pain relief, peak effect, and total effect, and tolerability of ibuprofen arginate with those of conventional ibuprofen in patients with moderate to severe pain associated with primary dysmenorrhea.
Patients were administered a single dose of ibuprofen arginate (200 or 400 mg), conventional ibuprofen (200 or 400 mg), or placebo during each of 5 menstrual cycles in a single-center, double-blind, randomized, double-dummy, 5-cycle, crossover study. Patients recorded their pain intensity and pain relief at regularly scheduled intervals (10, 20, 30, 40, 50, 60, and 90 minutes and 2, 3, 4, 5, and 6 hours) after taking the study medication, and all study observations were recorded in a patient diary. Pain intensity was rated using the following 4-point categoric rating scale: 0 = none, 1 = mild, 2 = moderate, and 3 = severe. Pain relief was rated on a 5-point scale as 0 = none, 1 = a little, 2 = some, 3 = a lot, and 4 = complete relief. Tolerability of ibuprofen arginate was based on a comparison of the incidence of spontaneously reported adverse events in each of the treatment groups.
One hundred four patients entered the study. Of these, 81.7% were white; the mean (SD) age was 27.5 (5.0) years. A total of 65.4% of patients reported moderate pain from dysmenorrhea, and the remaining 34.6% reported severe pain; 20.2% of patients did not complete the study. The median time to achieve meaningful pain relief was ∼30 minutes faster with ibuprofen arginate 400 mg than with either dose of conventional ibuprofen. Tolerability was similar across all treatments.
In this study population of patients experiencing acute pain as a result of primary dysmenorrhea, ibuprofen arginate was associated with effective, tolerable analgesia and a more rapid onset of action than conventional ibuprofen. The faster onset of analgesia may have a role in clinical practice in treating women with dysmenorrhea. A faster onset of action may be important to women whose personal relationships, productivity, or ability to sleep is being adversely affected by pain.
痛经会引起腹部疼痛性痉挛,可能扰乱女性的个人生活和工作效率。
本研究旨在比较精氨酸布洛芬与传统布洛芬对中度至重度原发性痛经相关疼痛患者的镇痛效果(包括起效时间、疼痛缓解持续时间、峰值效应和总体效应)及耐受性。
在一项单中心、双盲、随机、双模拟、5周期交叉研究中,患者在5个月经周期的每个周期内接受单剂量精氨酸布洛芬(200或400毫克)、传统布洛芬(200或400毫克)或安慰剂治疗。患者在服用研究药物后的定期时间点(10、20、30、40、50、60和90分钟以及2、3、4、5和6小时)记录疼痛强度和疼痛缓解情况,所有研究观察结果均记录在患者日记中。疼痛强度使用以下4级分类评分量表进行评定:0 = 无疼痛,1 = 轻度疼痛,2 = 中度疼痛,3 = 重度疼痛。疼痛缓解程度按5级评分:0 = 无缓解,1 = 稍有缓解,2 = 部分缓解,3 = 明显缓解,4 = 完全缓解。精氨酸布洛芬的耐受性基于各治疗组自发报告的不良事件发生率的比较。
104例患者进入研究。其中,81.7%为白人;平均(标准差)年龄为27.5(5.0)岁。共有65.4%的患者报告痛经为中度疼痛,其余34.6%报告为重度疼痛;20.2%的患者未完成研究。与两种剂量的传统布洛芬相比,400毫克精氨酸布洛芬实现有意义疼痛缓解的中位时间快约30分钟。所有治疗的耐受性相似。
在因原发性痛经而经历急性疼痛的本研究人群中,精氨酸布洛芬与有效、耐受性良好的镇痛相关,且起效比传统布洛芬更快。更快的镇痛起效可能在痛经女性的临床治疗中发挥作用。对于人际关系、工作效率或睡眠能力因疼痛而受到不利影响的女性来说,更快的起效可能很重要。